Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PRF1 | P14222 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | UGCG | Q16739 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26768095 | 0.88 | RAB9A (0.46) | METAP1SRD5A1PARP10PARP11NPC1 | |
| SCHEMBL21013541 | 0.86 | PRF1 (0.44) | NPC1PKMRAB9APRF1UGCG | |
| SCHEMBL435023 | 0.85 | DDB1 (0.48) | METAP1SRD5A1PARP10HTR2AHTR2C | |
| SCHEMBL26768092 | 0.84 | ESR1 (0.43) | METAP1SRD5A1MAOAMAOBAPP | |
| SCHEMBL26768087 | 0.82 | MEN1 (0.46) | METAP1PRF1APPMEN1KMT2A | |
| SCHEMBL5986406 | 0.81 | METAP1 (0.42) | METAP1SRD5A1PARP10PARP11HTR2A | |
| SCHEMBL424393 | 0.81 | GRM5 (0.57) | METAP1SRD5A1PARP10PARP11HTR2A | |
| SCHEMBL26767449 | 0.81 | MAOA (0.41) | MAOAMAOBAPPCRBN | |
| SCHEMBL25317766 | 0.79 | CRBN (0.47) | MKNK1MAOAMAOBUGCGAPP | |
| SCHEMBL31098598 | 0.79 | CRBN (0.47) | MKNK1MAOAMAOBUGCGAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397661-A1 | COMPOUND FOR DEGRADATION OF BCL-2 FAMILY PROTEINS AND MEDICAL APPLICATION THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024123853-A1 | TERNARY COMPLEX MODELLING FOR MOLECULAR GLUES | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024094819-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024096753-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4306520-A1 | THIOPHENE COMPOUND AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023239629-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2 | Plexium, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-4289827-A1 | FUSED RING DERIVATIVES CONTAINING 1,4-OXAZEPANE | Medshine Discovery Inc. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008008539-A2 | FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR | AMGEN INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | MYLK3, MYLK, CDK3 | METAP1 2239/4885SRD5A1 3751/4885PARP10 1913/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | METAP1 2843/4885SRD5A1 2198/4885PARP10 2499/4885 |
| US-20090186891-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | METAP1 2951/4885SRD5A1 554/4885PARP10 1229/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | METAP1 799/4885SRD5A1 3743/4885PARP10 1423/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | METAP1 1126/4885SRD5A1 3887/4885PARP10 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.